# A Study of GLB-001 in Patients With Myeloid Malignancies

> **NCT06378437** · PHASE1 · RECRUITING · sponsor: **Hangzhou GluBio Pharmaceutical Co., Ltd.** · enrollment: 108 (estimated)

## Conditions studied

- Polycythemia Vera
- Essential Thrombocythemia
- Myelofibrosis
- Myelodysplastic Syndromes
- Acute Myeloid Leukemia
- Myeloid Malignancy

## Interventions

- **DRUG:** GLB-001

## Key facts

- **NCT ID:** NCT06378437
- **Lead sponsor:** Hangzhou GluBio Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-24
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06378437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06378437, "A Study of GLB-001 in Patients With Myeloid Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06378437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*